HCM
BCRX icon

Highbridge Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Highbridge Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-16,600
Closed -$87K – 1633
2017
Q3 		$87K Buy
+16,600
New +$85K ﹤0.01% 1476

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Highbridge Capital Management's BCRX Position: Q2 2017 in Review

Highbridge Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2017, closing a stake of 68,097 shares — an estimated $572K sold.

Highbridge Capital Management first reported a position in BCRX in Q2 2014 and held it in 8 quarters. The position peaked at $2.05M in Q2 2015. 115 funds tracked by Wall St. Rank hold BCRX as of Q2 2017.

  • Highbridge Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 68,097 BioCryst Pharmaceuticals shares in Q2 2017, an estimated $572K.
  • Highbridge Capital Management first reported a position in BioCryst Pharmaceuticals in Q2 2014 and held it in 8 quarters.
  • Highbridge Capital Management's BioCryst Pharmaceuticals position peaked at $2.05M in Q2 2015.
  • 115 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2017.

Based on Highbridge Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.